Global Inflammatory Bowel Disease Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Inflammatory Bowel Disease Treatment Market is presumed to reach the market size of nearly USD 50.18 BN by 2030 from USD 27 BN in 2022 with a CAGR of 7.13% under the study period 2023 - 2030.

Inflammatory bowel disease (IBD) refers to several chronic disorders where the gut or digestive tract is inflamed. The digestive and intestinal tract is affected by both types of IBD. Some treatments can help with the management of this chronic illness. The goal of IBD treatment is to reduce inflammation. In the best-case situation, this might lead to symptom relief, long-term remission, and a decreased risk of complications. Surgery and drug therapy are used to treat IBD.

MARKET DYNAMICS:

The prevalence of ulcerative colitis and Crohn's disease is rising globally due to various factors, including lifestyle, societal and environmental changes, that will eventually fuel the market for inflammatory bowel disease treatment. In addition, a greater disease diagnosis rate and reimbursement policies in developed nations boost the market's expansion as early disease diagnosis becomes more important. Furthermore, inflammatory bowel disease treatment is surging as people become aware of the advantages of medications like biologics, corticosteroids, and others. Again, the increasing prevalence of promising pipeline medicines for inflammatory Bowel Disease treatment will propel market growth as more individuals become affected by IBD, increasing the demand for effective treatment alternatives.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of inflammatory bowel disease treatment. The growth and trends of inflammatory bowel disease treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the inflammatory bowel disease treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Crohn'S Disease
Ulcerative Colitis

By Drug Class

Aminosalicylates
Corticosteroids
TNF Inhibitors
IL Inhibitors
Anti-Integrin
JAK Inhibitors
Others

By Route Of Administration

Oral
Injectable

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Inflammatory Bowel Disease Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the inflammatory bowel disease treatment market include AbbVie Inc., Biogen, Johnson & Johnson Services Inc., Amgen Inc., UCB S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Pfizer Inc., Lilly. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11219393

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . INFLAMMATORY BOWEL DISEASE TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Drug Class
- 3.7.3 Market Attractiveness Analysis By Route Of Administration
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET ANALYSIS BY TYPE

6.1 Overview by Type
6.2 Historical and Forecast Data
6.3 Analysis by Type
6.4 Crohn's Disease Historic and Forecast Sales by Regions
6.5 Ulcerative Colitis Historic and Forecast Sales by Regions

7 . GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET ANALYSIS BY DRUG CLASS

7.1 Overview by Drug Class
7.2 Historical and Forecast Data
7.3 Analysis by Drug Class
7.4 Aminosalicylates Historic and Forecast Sales by Regions
7.5 Corticosteroids Historic and Forecast Sales by Regions
7.6 TNF inhibitors Historic and Forecast Sales by Regions
7.7 IL inhibitors Historic and Forecast Sales by Regions
7.8 Anti-integrin Historic and Forecast Sales by Regions
7.9 JAK inhibitors Historic and Forecast Sales by Regions
7.10. Others Historic and Forecast Sales by Regions

8 . GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

8.1 Overview by Route Of Administration
8.2 Historical and Forecast Data
8.3 Analysis by Route Of Administration
8.4 Oral Historic and Forecast Sales by Regions
8.5 Injectable Historic and Forecast Sales by Regions

9 . GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

9.1 Overview by Distribution Channel
9.2 Historical and Forecast Data
9.3 Analysis by Distribution Channel
9.4 Hospital Pharmacy Historic and Forecast Sales by Regions
9.5 Retail Pharmacy Historic and Forecast Sales by Regions
9.6 Online Pharmacy Historic and Forecast Sales by Regions

10 . GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1. Overview, Historic and Forecast Sales Analysis
- 10.3.2. North America By Segment Sales Analysis
- 10.3.3. North America By Country Sales Analysis
- 10.3.4. United State Sales Analysis
- 10.3.5. Canada Sales Analysis
- 10.3.6. Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1. Overview, Historic and Forecast Sales Analysis
- 10.4.2. Europe by Segment Sales Analysis
- 10.4.3. Europe by Country Sales Analysis
- 10.4.4. United Kingdom Sales Analysis
- 10.4.5. France Sales Analysis
- 10.4.6. Germany Sales Analysis
- 10.4.7. Italy Sales Analysis
- 10.4.8. Russia Sales Analysis
- 10.4.9. Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1. Overview, Historic and Forecast Sales Analysis
- 10.5.2. Asia Pacific by Segment Sales Analysis
- 10.5.3. Asia Pacific by Country Sales Analysis
- 10.5.4. China Sales Analysis
- 10.5.5. India Sales Analysis
- 10.5.6. Japan Sales Analysis
- 10.5.7. South Korea Sales Analysis
- 10.5.8. Australia Sales Analysis
- 10.5.9. Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1. Overview, Historic and Forecast Sales Analysis
- 10.6.2. Latin America by Segment Sales Analysis
- 10.6.3. Latin America by Country Sales Analysis
- 10.6.4. Brazil Sales Analysis
- 10.6.5. Argentina Sales Analysis
- 10.6.6. Peru Sales Analysis
- 10.6.7. Chile Sales Analysis
- 10.6.8. Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1. Overview, Historic and Forecast Sales Analysis
- 10.7.2. Middle East & Africa by Segment Sales Analysis
- 10.7.3. Middle East & Africa by Country Sales Analysis
- 10.7.4. Saudi Arabia Sales Analysis
- 10.7.5. UAE Sales Analysis
- 10.7.6. Israel Sales Analysis
- 10.7.7. South Africa Sales Analysis
- 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE INFLAMMATORY BOWEL DISEASE TREATMENT COMPANIES

11.1. Inflammatory Bowel Disease Treatment Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12 . COMPANY PROFILES OF INFLAMMATORY BOWEL DISEASE TREATMENT INDUSTRY

12.1. Top Company Share Analysis
12.2. Market Concentration Rate
12.3. AbbVie Inc.
- 12.3.1. Company Overview
- 12.3.2. Company Revenue
- 12.3.3. Products
- 12.3.4. Recent Developments
12.4. Biogen
- 12.4.1. Company Overview
- 12.4.2. Company Revenue
- 12.4.3. Products
- 12.4.4. Recent Developments
12.5. Johnson & Johnson Services Inc.
- 12.5.1. Company Overview
- 12.5.2. Company Revenue
- 12.5.3. Products
- 12.5.4. Recent Developments
12.6. Amgen Inc.
- 12.6.1. Company Overview
- 12.6.2. Company Revenue
- 12.6.3. Products
- 12.6.4. Recent Developments
12.7. UCB S.A.
- 12.7.1. Company Overview
- 12.7.2. Company Revenue
- 12.7.3. Products
- 12.7.4. Recent Developments
12.8. Novartis AG
- 12.8.1. Company Overview
- 12.8.2. Company Revenue
- 12.8.3. Products
- 12.8.4. Recent Developments
12.9. Takeda Pharmaceutical Company Limited
- 12.9.1. Company Overview
- 12.9.2. Company Revenue
- 12.9.3. Products
- 12.9.4. Recent Developments
12.10. Merck & Co. Inc.
- 12.10.1. Company Overview
- 12.10.2. Company Revenue
- 12.10.3. Products
- 12.10.4. Recent Developments
12.11. Pfizer Inc.
- 12.11.1. Company Overview
- 12.11.2. Company Revenue
- 12.11.3. Products
- 12.11.4. Recent Developments
12.12. Lilly
- 12.12.1. Company Overview
- 12.12.2. Company Revenue
- 12.12.3. Products
- 12.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies